Adoptive Induced Antigen-Specific Treg Cells Reverse Inflammation in Collagen-Induced Arthritis Mouse Model
Rheumatoid arthritis (RA) is a systemic autoimmune disease that may cause bone damage and worsening disability. Manipulating antigen-specific Treg cells is a promising approach to treat autoimmune disease since the immune suppressive function of Treg cells has the feature of antigen specificity which could avoid overall immune suppression. It has been known that the function of Treg cells is impaired in RA, and adoptive transfer of Treg cells is effective in suppressing RA. Here, we designed a new approach to generate antigen-specific Treg cells by culturing CD4+ T cells from mice with RA onset, and we also proved that the adoptive transfer of these antigen-specific Treg cells reversed the collagen-induced arthritis (CIA) progression by suppressing the key inflammatory cytokine TNF-α. Further analysis showed that the transferred Treg cells were stable in vivo. These findings suggest this novel approach may have clinical applications for treatment of autoimmunity, including RA and other autoimmune disorders.
Key WordsRA Treg cells Foxp3 TNF-α CIA antigen-specific autoimmunity
This work was supported by grants from the National Natural Science Foundations of China (NO.81600876), the Promotive Research Fund for Excellent Young and Middle-Aged Scientists of Shandong Province (BS2010YY054), the Science Foundation for The Youth Scholars of Sichuan University (NO.2016SCU11048), Shandong Medical and Health Technology Development (2014WSB04020), Shandong Provincial Natural Science Foundation (ZR2015HM060), and Shandong Provincial Science and Technology Development Projects Foundation (2013GSF31805).
Compliance with Ethical Standards
All animal studies were approved by the Subcommittee on Research and Animal Care (SRAC) of Shandong University and Sichuan University, and were performed by following the guidelines of Experimental Animal Center of Shandong University and Sichuan University for the use and care of live animals.
Conflict of Interest
The authors declare that there is no conflict of interest.
- 2.Saag, K.G., G.G. Teng, N.M. Patkar, J. Anuntiyo, C. Finney, J.R. Curtis, et al. 2008. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis and Rheumatism 59: 762–784.CrossRefPubMedGoogle Scholar
- 6.Rein, P., and R.B. Mueller. 2017. Treatment with biologicals in rheumatoid arthritis: An overview. Rheumatology and Therapy.Google Scholar
- 9.Chen, W., W. Jin, N. Hardegen, K.J. Lei, L. Li, N. Marinos, et al. 2003. Conversion of peripheral CD4+CD25-naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. The Journal of experimental medicine. 198: 1875–1886.CrossRefPubMedPubMedCentralGoogle Scholar
- 16.Kong, N., Q. Lan, M. Chen, J. Wang, W. Shi, D.A. Horwitz, et al. 2012. Antigen-specific transforming growth factor beta-induced Treg cells, but not natural Treg cells, ameliorate autoimmune arthritis in mice by shifting the Th17/Treg cell balance from Th17 predominance to Treg cell predominance. Arthritis and Rheumatism 64: 2548–2558.CrossRefPubMedPubMedCentralGoogle Scholar
- 20.Zhang, D., C. Chia, X. Jiao, W. Jin, S. Kasagi, R. Wu, et al. 2017. D-mannose induces regulatory T cells and suppresses immunopathology. Nature Medicine.Google Scholar